


Dear Friend of the UCLA Adult Congenital Heart Disease Center (ACHDC),

As the end of the year approaches, I would like to express my sincere gratitude for your continued support of the center's activities. As director, I am committed to advancing ACHDC's mission, responding directly to the needs of a growing patient population, leading the way in research, and training the next generation of experts in congenital heart disease (CHD).

I am pleased to describe some of our most recent achievements — not only to keep you apprised of our ongoing work, but also to acknowledge the profound impact that your generosity and involvement have on the center.




We recently published a 7th edition of *Perloff's Clinical Recognition of Congenital Heart Disease*, a textbook covering the full spectrum of CHD from infants to adults. This new edition, co-authored by Ariane J. Marelli, M.D., a professor in the Department of Medicine at McGill University, and me, includes new images throughout, as well as phonocardiograms, electrocardiograms, flow charts, and anatomic drawings. The original author, Dr. Joseph K. Perloff, who passed away in 2014, was the founding director of the Ahmanson/UCLA Adult Congenital Heart Disease Center. With specific, integrated findings for individual patients, this edition is a continuation of Dr. Perloff's legacy and classic approach to diagnosis and treatment.



ACHDC contributed to landmark research trials that led to FDA approval of Alterra/Sapien and Harmony pulmonary valve platforms. I am delighted to share that we are now one of the first centers in the world to implant these devices, which provide minimally

invasive treatment options for patients with severe pulmonary regurgitation with a native or surgically-repaired right ventricular outflow tract.

---



ACHDC faculty performed the first in-human use of the  $\bar{O}N\bar{O}$  retrieval system to remove an embolized pacemaker and balloon fragment from a patient. The  $\bar{O}N\bar{O}$  is a novel device designed to receive, align, compress, and remove non-biologic and biologic material from the vascular system. The success of this procedure speaks to the significant progress that has been made in reducing morbidity and mortality associated with device embolization in the human body.  $\bar{O}N\bar{O}$  was cleared by the FDA in May 2022 and is available at select sites throughout the United States.

---

These highlights from our year reflect a level of excellence that would not be possible without your support. My ACHDC colleagues and I deeply appreciate each act of philanthropy, large or small.

We kindly ask you to extend your partnership with us by [donating online](#) today. For other ways to give, please contact Lindsey Walton, Director of Development, at [LSWalton@mednet.ucla.edu](mailto:LSWalton@mednet.ucla.edu) or 424-946-6102. Your gift will directly benefit ACHDC's innovative research efforts, outstanding educational programs, and comprehensive patient care.

Thank you for your consideration. I wish you and your loved ones a safe and joyful holiday season.

Sincerely,

Jamil Aboulhosn

Director, Ahmanson/UCLA Adult Congenital Heart Disease Center  
Streisand Chair in Cardiology  
Director, UCLA Adult Congenital Heart Disease Center

[uclahealth.org/medical-services/heart/achd](http://uclahealth.org/medical-services/heart/achd)

**GIVE NOW**

*If you do not wish to receive further fundraising information from UCLA Health Sciences, please either call us at (855) 364-6945 or email us at [hsd\\_optoutucla@mednet.ucla.edu](mailto:hsd_optoutucla@mednet.ucla.edu) and provide your name, address, phone number, and from which department you are requesting to be removed.*

*Please review UCLA and the UCLA Foundation's Disclosure Statements for Prospective Donors at [www.uclafoundation.org/disclosures](http://www.uclafoundation.org/disclosures).*

M-35925